30 results about "TNF inhibitor" patented technology

Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.

Methods for treating an inflammatory or an immune condition are described. Methods for treating an inflammatory or an immune condition with IL-1 inhibitors and an inhibitor of B cell or T cell activation are described. Methods for treating an inflammatory or an immune condition with TNF inhibitors and an inhibitor of B cell or T cell activation are described.

The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

The invention provides a primer group, an application, a product and a method for detecting SNP (single nucleotide polymorphism) loci related to drug metabolism capacity of rheumatic immunological diseases, and relates to the technical field of biology. The primer group for detecting the SNP loci related to the drug metabolism capacity of the rheumatic immunological diseases can be used for detecting metabolism capacity of an immunosuppressor, metabolism capacity of an immunomodulator, metabolism capacity of an anti-inflammatory agent, metabolism capacity of a TNF inhibitor, metabolism capacity of a B cell regulator, metabolism capacity of an IL-6 inhibitor, metabolism capacity of a uric acid lowering agent and metabolism capacity of a uricosuric agent. The primer group is designed for main mutation sites related to common drug metabolism of the rheumatic immunological diseases, can realize specific detection for locus mutation related to common drug metabolism of the rheumatic immunological diseases, and can greatly shorten detection cycle and reduce detection cost.

This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF).Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and / or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.

The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.

The invention discloses an inhibitor of mitogen protein kinase p38 as well as a preparation method and application of the inhibitor. The inhibitor is an amino nicotinamide compound or an amino pyrazinamide compound. The preparation method mainly comprises the following steps: nitrifying 6-hydroxyl nicotinic acid to generate 5-nitro-6-hydroxyl nicotinic acid; treating 5-nitro-6-hydroxyl nicotinic acid with phosphorus oxybromide so as to convert 5-nitro-6-hydroxyl nicotinic acid into 5-nitro-6-bromonicotinic acid; carrying out Suzuki coupling reaction on 5-nitro-6-bromonicotinic acid to generate 5-nitro-6-aryl nicotinic acid; reacting 5-nitro-6-aryl nicotinic acid with oxalyl chloride to obtain 5-nitro-6-aryl nicotinamide; and carrying out hydrogenation reduction on a nitro group to obtain 5-amino-6-aryl nicotinamide. According to the invention, the inhibitor of the mitogen protein kinase p38 is a small molecular inhibitor which can effectively inhibit the synthesis of in vivo TNF (tumor necrosis factor)-alpha, has the curative effect of a large molecular inhibitor on diseases, is low in production cost, can be orally taken so that a patient can conveniently use the inhibitor, has good practicability, and can generate good economic and social effects.

A treatment for inflammatory dermatoses, such as psoriasis and atopic dermatitis (eczema), is disclosed that utilizes topical administration of a halogenated xanthene, such as rose bengal, together with administration of one or more complementary targeted systemic dermatology therapies, preferably a therapy that addresses the inflammatory pathway and is other than an NSAID that is a COX-1 and / or COX-2 inhibitor. Examples of complementary targeted systemic therapeutic ingredients include: corticosteroids, including betamethasone dipropionate and fluocinonide; dithranol; vitamin D analogs, including calcipotriol; and retinoids, non-biologics including methotrexate, ciclosporin, hydroxycarbamide, and fumarates including dimethyl fumarate; as well as one or more biologics, including antibodies or paratope-containing antibody portions to TNF-α, antibodies to pro-inflammatory cytokines interleukin-12, interleukin-23 and interleukin-17, and TNF inhibitors. Treatment of other epithelial tissue, such as the lining of the gut, is also disclosed.